New therapy protects lungs from runaway inflammation

Mar 11, 2009

A novel anti-inflammatory therapy designed by Vanderbilt University Medical Center investigators prevents acute lung injury in mice exposed to an inflammation-causing toxin, the researchers report in the journal Molecular Therapy.

The new may offer a way to protect the lungs from the "runaway inflammation" that can accompany bacterial or , said Jacek Hawiger, M.D., Ph.D., the leader of the research team that has pioneered the new approach.

" is an extremely ," noted Hawiger, chair of the Department of Microbiology & Immunology.

The immune system sometimes overreacts to lung infection and produces excessive concentrations of inflammatory signals (cytokines and chemokines), which can damage the fine architecture of the lungs and lead to life-threatening acute respiratory distress syndrome (ARDS). Such damage is most likely when has both viral and bacterial causes - for example from combined influenza and Staphylococcus aureus infections.

"We believe that in addition to controlling the infection with antibacterial and antiviral agents, we need therapies that reduce this inflammation-induced collateral damage to the lung tissue," Hawiger said. "This would allow both faster clearance of the infecting organisms and faster healing of the lung."

Several years ago, Hawiger and colleagues began searching for new targets for anti-inflammatory therapy. They reasoned that a protein called NF-kappa-B - the "master regulator" of genes that encode mediators of inflammation - might make a good target.

The researchers knew that NF-kappa-B moves from the cell cytoplasm to the nucleus (where it is active) in response to cellular injury or microbial agents, and they decided to try to block this nuclear translocation.

They designed a small protein fragment - a peptide - that mimicked the nuclear transport "signal," hoping that it would compete with, and block, NF-kappa-B's movement to the nucleus. To get the peptide into cells, the team took advantage of the cellular mechanism that proteins use to cross membranes and engineered a membrane-crossing motif onto the therapeutic peptide.

"To our delight, we found that this peptide crossed the cell membrane and stopped NF-kappa-B in its tracks, blocking it from going to the nucleus in response to conditions which cause inflammation," Hawiger said.

It turned out that the inhibitor worked even more broadly than the researchers expected. The peptide blocks a "shuttle" that ferries not only NF-kappa-B to the nucleus, but also a group of additional stress-responsive proteins. The nuclear shuttle protein represents a new intracellular target for anti-inflammatory therapy, Hawiger said.

The researchers tested the effectiveness of this cell-penetrating peptide therapy against inflammation in a mouse model of acute lung injury.

They exposed mice to staphylococcal enterotoxin B (SEB), an immunotoxin produced by methicillin-resistant S. aureus (MRSA). SEB generates a "storm" of inflammatory signals that damages the lungs and causes ARDS and multiple organ dysfunction. Airborne SEB caused fatal ARDS in non-human primates.

Treatment of SEB-exposed mice with the nuclear transport inhibitor suppressed the inflammatory storm in the lungs. Inflammatory cells, whose numbers increase 2.5-fold after SEB exposure, remained normal in peptide-treated mice. Peptide therapy also suppressed the levels of chemokines and cytokines and prevented injury to the lung's blood vessels.

"It's very reassuring to us that this single agent, which targets the nuclear import shuttle, suppressed the production of all of these harmful mediators of excessive inflammation," Hawiger said.

The investigators are pursuing pre-clinical studies of the peptide therapy with hopes that it will lead to improved adjunctive therapies for life-threatening pneumonia caused by multiple germs.

Source: Vanderbilt University Medical Center

Explore further: Japan lab cannot repeat ground-breaking cell finding: reports

add to favorites email to friend print save as pdf

Related Stories

AT&T to put 8,000 natural-gas vehicles on road

Mar 11, 2009

(AP) -- AT&T Inc. said Wednesday it will spend up to $350 million over five years to buy more than 8,000 Ford Motor Co. vans and trucks, then convert them to run on compressed natural gas.

Small molecules block cancer gene

Mar 10, 2009

Finding molecules that block the activity of the oncogene Stat 3 (signal transducer and activator of transcription) required screening literally millions of compounds, using computers that compared the structure of the cancer-causing ...

US struggles to pinpoint cyber attacks: Top official

Mar 10, 2009

The United States often cannot quickly or reliably trace a cyber attack back to its source, even as rival nations and extremists may be looking to wage virtual war, a top official warned Tuesday.

Space Station video now live on Internet -- mostly

Mar 11, 2009

(AP) -- NASA has started beaming live video from just outside the International Space Station, but there's a catch: The online feeds are available only when the station's crew is asleep or off duty.

Recommended for you

Why does rotting food smell bad?

Dec 16, 2014

When food goes bad and starts to become pungent, it is most often due to the growth of spoilage microbes such as bacteria, yeasts and mold. Odors can come from two sources: chemicals that are released from ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.